Skip to content
Parakho

Windlas Biotech Ltd

NSE WINDLASBSE 543329windlas.com

Q1 FY27, unaudited

Revenue
₹248.10 Cr
Profit after tax
₹17.65 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations248.10+18.09%904.09
Other income5.11−2.41%17.80
Total income253.21+17.59%921.89
Employee benefit expense44.43+37.86%152.09
Finance costs1.65+56.10%4.83
Depreciation & amortisation7.21−3.25%30.74
Total expenses230.28+19.89%834.96
Profit before tax22.94−1.38%86.93
Tax expense5.28−5.54%20.50
Profit after tax17.65−0.07%66.44
Total comprehensive income17.61−0.53%66.55
Earnings per share
Earnings per share, basic₹8.46₹31.59
Earnings per share, diluted₹8.32₹31.14

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Windlas Biotech reported its highest ever quarterly revenue of Rs 248 crore in Q1 FY27, up 18% year-on-year, marking 14 consecutive quarters of record revenue. The Generic Formulations CDMO vertical grew 29% year-on-year while Trade Generics & Institutional revenue declined following discontinuation of codeine-based products, and Exports grew 79% year-on-year. Management said Plant 6 remains on track for commercialization in H1 FY27 and discussed capacity, working capital and API price volatility during the quarter.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 55 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.